Syngene, a World-leading Contract Research Organization, Chooses Reaxys(R) to Enhance Productivity and Competitiveness

By Elsevier, PRNE
Thursday, May 12, 2011

Reaxys is an Online Workflow Solution Used by Research Chemists in Lead Identification to Fuel Their Drug Discovery Processes

FRANKFURT, Germany, May 13, 2011 - Elsevier, the world's leading publisher of scientific content and online
solutions announced today that Syngene, India's first contract research
organization, has signed a multi-year contract that will provide unlimited
access to Reaxys for all Syngene researchers. Reaxys will help Syngene
enhance its R&D competitiveness and productivity in the ever-expanding and
highly competitive Indian pharmaceutical, chemical and agrochemical research

Dr. Manoj Nerurkar, Head of Small Molecule Discovery & Development at
Syngene, said of the agreement, "It's critical for our scientists to have
immediate access to the relevant chemical information. We have to generate
maximum output with a minimum number of experiments. The insights Reaxys
gives us into possible synthetic routes and validated physical property data
is crucial in ensuring that when we start in the lab we will generate better
output in less time. Starting with Reaxys, we can be sure that the
information is reliable and we will not be led down any false routes."

Syngene is already a preferred research service provider to leading
players in global pharmaceutical and chemical industries who continue to
invest and commit to enlarging their R&D activities in India. Access to
Reaxys' validated, curated chemical information will be a key factor in
helping Syngene maintain this position.

"Reaxys is dedicated to providing the relevant information that will
enable researchers to innovate effectively: to act immediately on their
findings from Reaxys and apply them directly in the lab," said Mark van
, Managing Director, Pharma and Biotech Group, Elsevier. "We are
pleased to extend our relationship with Syngene and we look forward to
continuing to support it in its ongoing R&D efforts."

About Syngene

Established in 1994, Biocon subsidiary Syngene is an internationally
reputed contract research and manufacturing organisation with
multidisciplinary skills in chemistry, biology, process development and
scale-up, formulation and analytical development and preclinical services.
India's first Contract Research Organization (CRO), it has successfully
partnered with leading players in global pharmaceutical, biotechnology,
chemical and agrochemical industries across a wide range of discovery and
development programmes.

From early stage discovery and process development through to cGMP
manufacturing, it provides customised services to pharmaceutical and
biotechnology majors on a strong platform of confidentiality and intellectual
property protection. Its deep scientific talent pool and state-of-the-art R&D
and production facilities enable it to enhance productivity and accelerate
delivery of all projects with the highest degree of professionalism.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. The company works in partnership
with the global science and health communities to publish more than 2,000
journals, including The Lancet ( and Cell
(, and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier's online solutions include
SciVerse ScienceDirect (, SciVerse Scopus
(, Reaxys (, MD
Consult ( and Nursing
Consult (,
which enhance the productivity of science and health professionals, and the
SciVal suite ( and MEDai's Pinpoint Review
(, which help research and health care institutions
deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier ( employs 7,000 people
worldwide. The company is part of Reed Elsevier Group PLC (, a world-leading publisher and
information provider, which is jointly owned by Reed Elsevier PLC and Reed
Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London
Stock Exchange), RUK and ENL (New York Stock Exchange).

    Media Contact
    Tom Reller
    Vice President, Global Corporate Relations


Pharmaceuticals News

May 13 News

will not be displayed